Iclusig (ponatinib), a tyrosine
kinase inhibitor recently approved
for PBS funding is the subject of
this week’s Repatriation General
Hospital Pharmacy E-Bulletin.
The indications for the use of
the product are detailed along
with some elements of the
phase II trial which tipped the
approval, dosing, drug interactions
of which to be aware and the
product’s pharmacodynamics and
pharmacokinetics.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Nov 15
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.